Clinical Exome Sequencing(CES)_ONCO

Clinical Exome Sequencing (CES)_ONCO

Clinical Exome Sequencing (CES)_ONCO is an advanced genetic test that analyzes the protein-coding regions (exons) of thousands of genes associated with inherited cancer syndromes and cancer-related disorders. Using Next-Generation Sequencing (NGS), it identifies disease-causing genetic variants that may increase cancer risk, assist in diagnosis, guide targeted treatment decisions, and support genetic counseling for patients and their families.

Why is this test performed?

• Detect hereditary cancer predisposition syndromes.
• Identify pathogenic genetic variants linked to various cancers.
• Support precision oncology and personalized treatment planning.
• Assist in risk assessment for family members.
• Help determine eligibility for targeted therapies and clinical trials.

Who should consider this test?

• Individuals with a strong family history of cancer.
• Patients diagnosed with cancer at a young age.
• People with multiple primary cancers.
• Families with suspected hereditary cancer syndromes.
• Individuals advised by an oncologist or genetic counselor for comprehensive genetic evaluation.

Sample Required

• Peripheral Blood (EDTA)

Technology Used

• Next-Generation Sequencing (NGS)
• Comprehensive Clinical Exome Analysis
• Bioinformatics-based variant interpretation following established clinical guidelines.

Benefits

• Comprehensive evaluation of clinically relevant genes.
• Early identification of inherited cancer risk.
• Supports personalized treatment and surveillance strategies.
• Enables informed healthcare decisions for patients and relatives.
• High diagnostic value for genetically heterogeneous cancer conditions.

Preparation

No special preparation is required. Genetic counseling before and after testing is recommended to understand the results and their implications.